Ambrožič Jana, Cvijič Marta, Bervar Mojca, Mušič Špela, Bunc Matjaž
Clinical Department of Cardiology, University Medical Centre Ljubljana, Zaloška 7, 1000, Ljubljana, Slovenia.
Clinical Department of Anesthesiology and Perioperative Intensive Therapy, University Medical Centre Ljubljana, Zaloška 7, 1000, Ljubljana, Slovenia.
Wien Klin Wochenschr. 2018 Mar;130(5-6):211-219. doi: 10.1007/s00508-017-1295-7. Epub 2017 Dec 4.
MitraClip is a percutaneous mitral repair technology increasingly used for high surgical risk patients with primary or secondary mitral regurgitation. We describe initial Slovenian experience with MitraClip and discuss the importance of identifying the suitable candidates for this procedure.
We retrospectively analyzed the first 10 patients (mean age 75.6 ± 6.9 years, logistic Euroscore 28.4 ± 10.9%) with severe and moderate to severe mitral regurgitation (8 secondary, 1 primary and 1 mixed etiology) who underwent a MitraClip procedure between January 2015 and February 2017.
Acute reduction of mitral regurgitation was achieved in all but one patient (90%). There were no periprocedural mortalities and at short to mid-term follow-up (median 12 months, interquartile range 3-15 months). In eight patients improvement of functional class was observed at discharge. No functional improvement was achieved in a patient with advanced ischemic cardiomyopathy, and in a patient with degenerative mitral disease in whom the MitraClip procedure had failed necessitating mitral valve surgery. One patient experienced late leaflet detachment and was effectively managed with a second MitraClip procedure. There were two vascular complications at the access site and one percutaneous closure of an iatrogenic atrial septal defect.
Our initial experiences with a small number of patients indicate that percutaneous mitral repair with MitraClip is a feasible and safe method in high-risk patients. Special attention should be paid to careful patient selection including detailed echocardiographic evaluation of mitral valve anatomy, technical performance and final result, particularly at the beginning of the learning curve in order to reduce the rate of serious complications.
MitraClip是一种经皮二尖瓣修复技术,越来越多地用于具有原发性或继发性二尖瓣反流的高手术风险患者。我们描述了斯洛文尼亚使用MitraClip的初步经验,并讨论了确定该手术合适候选者的重要性。
我们回顾性分析了2015年1月至2017年2月期间接受MitraClip手术的10例严重和中重度二尖瓣反流患者(平均年龄75.6±6.9岁,逻辑欧洲评分28.4±10.9%),其中8例为继发性,1例为原发性,1例为混合病因。
除1例患者外,所有患者(90%)二尖瓣反流均实现急性减少。围手术期无死亡病例,短期至中期随访(中位时间12个月,四分位间距3 - 15个月)。8例患者出院时功能分级得到改善。1例晚期缺血性心肌病患者和1例退行性二尖瓣疾病患者(MitraClip手术失败,需进行二尖瓣手术)功能未改善。1例患者出现瓣叶晚期脱离,通过第二次MitraClip手术有效处理。穿刺部位有2例血管并发症,1例经皮闭合医源性房间隔缺损。
我们对少数患者的初步经验表明,使用MitraClip进行经皮二尖瓣修复在高危患者中是一种可行且安全的方法。应特别注意仔细选择患者,包括对二尖瓣解剖结构进行详细的超声心动图评估、技术操作和最终结果,尤其是在学习曲线初期,以降低严重并发症的发生率。